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Signalinged by adipose tissue, regulates energy balance in the hypothalamus and is
involved in fertility, immune response and carcinogenesis. The existence of disorders related to leptin deﬁcit
and leptin overabundance calls for the development of drugs activating or inhibiting the leptin receptor
(ObR). We synthesized four proposed receptor-binding leptin fragments (sites I, IIa and IIb, III), their
reportedly antagonist analogs, and a peptide chimera composed of the two discontinuous site II arms. To
assess the pharmacological utility of leptin fragments, we studied the peptides' ability to stimulate the
growth of ObR-positive and ObR-negative cells. The combined site II construct and site III derivatives
selectively reversed leptin-induced growth of ObR-positive cells at mid-nanomolar concentrations.
However, these peptides appeared to be partial agonists/antagonists as they activated cell growth in the
absence of exogenous leptin. A designer site III analog, featuring non-natural amino acids at terminal
positions to decrease proteolysis and a blood–brain barrier (BBB) penetration-enhancing carbohydrate
moiety, proved to be full agonist to ObR, i.e., stimulated proliferation of different ObR-positive but not ObR-
negative cells in the presence or absence of leptin. This glycopeptide bound to isolated ObR on solid-phase
assays and activated ERK-1/2 signaling in ObR-positive MCF-7 cells at 100–500 nM concentrations. The
glycopeptide was stable in mouse serum, readily crossed endothelial/astrocyte cell layers in a cellular BBB
model, and was distributed into the brain of Balb/c mice after intraperitoneal administration. These
characteristics suggest a potential pharmaceutical utility of the designer site III glycopeptide in leptin-
deﬁcient diseases.
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Leptin is a neurohormone that acts in the hypothalamus to regulate
energy balance and food intake [1]. Recessive mutations in the leptin
(obese, ob) or its receptor ObR (diabetes, db) gene result in profound
obesity and type II diabetes mellitus [2]. Further studies demonstrated
that in addition to its role as a neurohormone, leptin can modulate
immune response, fertility, and hematopoiesis, acting as a mitogen,
metabolic regulator, or pro-angiogenic factor [1]. The full-length native
leptin protein is currently undergoing ten different clinical trials against
a series of leptin-deﬁcient diseases, including lipodystrophy, diet-in-
duced food craving, and hypothalamic amenorrhea. In the past, the
results of clinical trialswith leptin as a therapeutic agent for obesity have
been disappointing, largely due to leptin resistance in obese people as
well as disadvantageous pharmacological parameters of recombinant
leptin drug leads [3].
New evidence indicates that leptin can be involved in carcinogen-
esis [4]. Leptin stimulates breast cancer cell growth, interfereswith the
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hormone-dependent tumor types, such as breast and colorectal cancer,
leptin and ObR have been found overexpressed [9–12] and the leptin/
ObR system has been proposed to serve as a novel prognostic marker
[13]. It has been repeatedly argued that leptin is a novel pharmaceu-
tical target, and leptin antagonists may represent a new family of
cancer drugs. Indeed, preliminary data demonstrate that a peptide
comprising residues 70–95 of leptin binds speciﬁcally and with high
afﬁnity (Ki∼60 pM) to ObR and inhibits its functions in rabbit
endometrial cells and mouse mammary cancer cells [14–15].
The activities of leptin are mediated through the transmembrane
leptin receptor ObR [16–17]. In human tissues, at least four isoforms of
ObR with different COOH-terminal cytoplasmic domains have been
described [18]. The full (long) form of ObR (ObRl) has 1165 amino acids
(Mw∼150,000–190,000) and contains the extracellular, transmem-
brane, and intracellular domains. The extracellular domain binds
ligand, whereas the intracellular tail recruits and activates signaling
substrates. ObRl is highly expressed in the hypothalamus [19],
however, lower levels of ObRl have been identiﬁed in many peripheral
organs [20–25].
The signaling pathways activated by ObRl include the classic
cytokine JAK2/STAT3 (Janus kinase 2/signal transducer and activator of
transcription 3) pathway; the Ras/ERK1/2 (Ras/extracellular signal-
regulated kinases 1/2) signaling cascade; and the PI-3K/Akt/GSK3
(phosphoinositide 3 kinase/protein kinase B/glycogen synthase kinase
3) growth/antiapoptotic pathway [26]. In addition, leptin has been
found to induce PLC (phospholipase C)-γ, PKC (protein kinase C), p38
kinase, and nitric oxide (NO) production [19,27–28]. Ultimately, induc-
tion of ObRl can activate several genes involved in cell proliferation,
including c-fos, c-jun, junB, egr-1, and socs3, and upregulate the ex-
pression angiogenic factors, such as VEGF [27–29].
Leptin is transported across the BBB by a saturable transport system
[30–32]. Mature human leptin is secreted as a 146-amino acid protein,
with a bundle of 4 helices (helices A–D) with an up-up-down-down
topology [33]. Superimposition of leptin's sequence with other
cytokines, such as human IL-6, bovine G-CSF, human oncostatin M,
etc., reveals three potential dual-chain receptor binding sites (sites I–III),
mostly around the pairwise helices [34]. The receptor binding site
around residue 40 is labeled as site I, those at the veryN-terminus and in
themiddle of theprotein as site II and theoneat theC-terminus as site III
(Fig.1). Interferingwith these binding surfacesmay increase or decrease
the efﬁciency of downstream ObR signaling. Single-point mutations in
full-sized leptin at binding site III drastically attenuate the agonistic
activity and convert those mutants into both partial antagonists and
weak agonists [35]. Remarkably, mutation of Tyr119 to alanine yields a
ligand with 95% antagonistic activity without affecting the binding
strength to the receptor, indicating that the leptin/ObR interface can
serve as target for anti-neoplastic drug design. Recombinant leptin
featuring a Ser120Ala, Thr121Ala doublemutation atObR binding site III
avidly binds to the CRH2 domain of ObR but fails to induce proper
downstream signaling [34]. In vivo, the mutated protein induces body
weight increases. These ﬁndings identify the ﬁrst half of helix D and theFig. 1. Schematic representation of the leptin protein structure. The letters represent the
four helices (A–D) and the standing numbers indicate the starting and ending residues
of A, B, C and D. The proposed ObR-binding sites (Sites I–III) are indicated above the
scheme (underlined). Site II is composed of two separate leptin domains, Site II a and b.
The numbers under the scheme in italics indicate the approximate location of the
synthetic peptides, using the Code numbers listed in Table 1. Leptin numbering is based
on [34].unstructured region N-terminal to it as a major antagonist site. Another
potential antagonist site is located before helix B,where alaninemutants
of amino acids 39–42 in full-sized human and ovine leptins act as
antagonists, i.e. they bind ObR with an afﬁnity similar to the wild-type
hormone, have no agonistic activity at the protein level and speciﬁcally
inhibit leptin action in several leptin-responsive in vitro bioassays
without changing the secondary structure [35]. The region around
residue 40 is designated as ObR binding site I.
While all three sites have some discontinuous character [34], for
binding site II both arms of the bivalent ligand are unequivocally
identiﬁed. One of them comprises the N-terminal hexadecapeptide
and the other is a fragment between Gln75 and Leu86 [36]. While
predicted hydrophobic cleft residues Leu89 and Phe92 are excluded
from the interaction, hydrophobic interactions of Leu13 and Leu86 in
leptinwith Leu504 in CRH2 of ObR form the center of the leptin/CRH2
interface. This identiﬁes helix C in leptin as the thirdmajorObRbinding
site (site II, fragment b).
Most of the studies above used the full-length native leptin protein.
The multiple roles that leptin plays in various biological processes
suggest that it is not straightforward to obtain true agonists or an-
tagonists that do not change the downstream signaling effect upon
varying environmental conditions. Indeed, the emergence of both
partial antagonists andweak agonists as listed abovemay indicate that
dependingon individual cell context aswell as the presence or absence
of native, unmodiﬁed leptin, the samemutant protein or large subunit
can trigger different downstream signaling responses. Thus, their use
in human or veterinary therapymightmeet regulatory opposition. Our
long term goals are to develop full agonist and antagonist peptide
ligands of the leptin receptor. Ideally, to antagonize ObR, we envision a
short peptide that does not cross the BBB and is able to inhibit ObR
mitogenic signaling in cancer cells with or without native leptin
present. On the other hand, to mimic leptin functions under leptin-
deﬁcient pathological conditions, we envision a small and mono-
functional full agonist possessing BBB penetrating and full signaling
abilities in the presence or absence of leptin. Consequently, this study
was established to
1) Analyze the antagonist activities of the reported alaninemutants at
the peptide level in the absence or presence of exogenous full-sized
native leptin;
2) Verify the activity of short leptin fragments corresponding to all
three predicted ligand sites on cells expressing ObR and the lack of
toxicity of cells lacking ObR;
3) Develop novel leptin peptide derivatives for potential use as ObR
agonists or antagonists.
We found that all peptides designed as potential antagonists had
partial agonist/antagonist properties. On the other hand, wewere able
to develop a modiﬁed peptide corresponding to site III as a full ObR
agonist. This 12-residue peptidomimetic bound ObR in vitro and
induced ERK-1/2 signaling in ObR-positive cells. In addition, the pep-
tide was extremely resistant to serum proteases due to the incorpora-
tion of unnatural amino acids at exopeptidase cleavage positions, had
the propensity to cross BBB in vitro and was readily distributed
throughout the body including the brain in Balb/c mice in vivo.
2. Materials and methods
2.1. Peptide synthesis
The peptideswere synthesized by solid-phasemethods. The peptide chain assembly
was made on either a CEM Liberty microwave-assisted automated synthesizer or a
MultiSynTech SYROmultiple peptide synthesizer using TentaGel S-Ram-Fmoc resinwith
an initial load of 0.3 mmol/g (Advanced ChemTech). Standard Fmoc-chemistry was used
throughout [37] with a 4-molar excess of the acylating amino acids. Non-natural amino
acidswere coupledmanually to ensure completion. Before cleavage, the resinswere split
into two equal parts, and one half was endcappedwith 5(6)-carboxyﬂuorescein. Peptide
13 was also N-terminally conjugated to the ﬂuorescent dye DY675. Both unlabeled
and labeled peptides were cleaved from the solid support with triﬂuoroacetic acid (TFA)
in the presence of thioanisole (5%), and water (5%) as scavengers. After cleavage, the
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(RP-HPLC), (preparative runs: isocratic elution of 5% acetonitrile in 0.1% TFA for 5 min
followed by a linear gradient from 5% to 65% acetonitrile for 120min). The ﬁnal products
were characterized by RP-HPLC (during the analytical runs the same gradient is de-
veloped over a 45 min period) and matrix-assisted laser ionization/desorption mass
spectroscopy (MALDI-MS). The carbohydrate protecting acetyl groups were removed
with a 10-min treatmentwith 0.01MNaOHand the reactionmixtureswere immediately
neutralized with an equal amount of 0.01 M HCl. Mass spectra (PerSeptive Biosystems,
Voyager DE instrument) identiﬁed correct and clean samples (Table 1).
2.2. Serum stability
For serum stability studies, 250 µL of an aqueous peptide stock solution containing
about 0.8 mg/mL peptide was added to 2.5 mL 25% aqueous pooled mouse serum [38].
The peptide-serum mixture was thermostated at 37 °C. After 0 min, 45 min or 60 min,
90 min, 2 h, 4 h, and 8 h, three 210 μL samples of each peptide were taken, and
precipitated by the addition of 40 µL 15% aqueous trichloroacetic acid. The samples
were stored at 4 °C for 20 min and centrifuged. The supernatants were immediately
frozen on dry-ice and 220 µL of each was analyzed on RP-HPLC and/or MALDI-MS.
2.3. Cell proliferation
Human leptin was purchased from R&D Systems and used at the concentration of
100 ng/mL (approximately 6 nM). MCF-7 and DU-145 cells naturally expressing ObR
were grown in a standard medium DMEM:F12 plus 5% fetal bovine serum. ObR-
negative MCF-10 human mammary epithelial cells were grown in mammalian
epithelial growth serum-free medium (SFM) supplemented with 100 ng/mL cholera
toxin. Seventy percent conﬂuent cultures were synchronized in SFM (DMEM plus 10 μM
FeSO4, plus 0.5% bovine serum albumin, BSA) for 24 h and then treated with leptin and/
or peptides (different doses) for 5 days. Cell numbers before and after treatment were
determined by counting the cells with trypan blue exclusion. All assays were done in
triplicate and repeated 3–6 times. The changes in cell number vs control SFM were
determined as percentage decrease/increase and expressed as means±standard error
(SE). The results were statistically evaluated by Student's t-test and analysis of variance
(ANOVA). Values of pb0.05 were considered statistically signiﬁcant.
2.4. Dot-blot and ELISA
The leptin fragments were dissolved in electroblot transfer buffer (25 mM Tris and
192 mM glycine buffer containing 20% methanol) and were applied to either a
nitrocellulose membrane or dried down to ELISA plates [39]. The solid surfaces were
blocked with 5% BSA in a PBS-0.5% Tween 20 buffer (PBST) for 3 h at room temperature
and were incubated with 10 μg/mL solution of human IgG Fc-conjugated ObR ex-
tracellular domain (R&D Systems) dissolved in Tris-buffered saline–0.1% Tween 20
buffer (TBST) containing 1% BSA for 1 h. A goat monoclonal antibody (Ab), recognizing
the N-terminus of human ObR (Santa Cruz Biotechnology) was added as a primary
antibody at 1:1000 dilution overnight at 4 °C followed by a horseradish peroxidase-
(HRP) conjugated anti-goat IgG donkey antibody for the dot-blot or HRP-conjugated
anti-goat Fc mouse antibody for ELISA, respectively (both at 1:15,000 dilution in PBSTTable 1
Peptide sequences and analytical data of synthetic leptin fragments and peptidomimetics
Peptide
code
Residue numbers relative
to consensus sequence
Tentative ObR
binding site
Basic sequence
1 3–18 II fragment a IQKVQDDTKTLIKTIV
2 36–49 I VTGLDFIPGLHPIL
3 36–49 I VTGAAFIPGLHPIL
4 70–89 II fragment b SRNVIQISNDLENLRDLLHV
5 3-18-GGG-70-89 Combined II
construct
IQKVQDDTKTLIKTIVGGG
SRNVIQISNDLENLRDLLHV
6 117–132 III SGYSTEVVALSRLQGS
7 117–132 III SGYAAEVVALSRLQGS
8 118–129 III GYSTEVVALSRL
9 119–129 III YSTEVVALSRL
10 118–129 III GYSTEVVALSRL
11 119–129 III YSTEVVALSRL
12 119–130 III YSTEVVALSRLQ
13 119–130 III YSTEVVALSRLQ
14 118–130 III GYSTEVVALSRLQ
15 Ac-EVVALSRL-Dap(Ac) Synth
during preparation of 12/13
Modiﬁed amino acid residues are printed in bold. Glc stands for β-linked D-glucose, D-G
propionic acid.and 1% BSA for 1 h at room temperature). Between reagents, the solid surfaces were
extensively washed with PBST. Then, the membrane was treated with chemilumines-
cence luminol oxidizer (NEN) for 1 min and exposed to X-Omat blue XB-1 ﬁlm (Kodak)
for 10 s. The ELISAwas developedwith an HRP ELISA kit featuring tetramethylbenzidine
as substrate and sulfuric acid as stop solution. Absorbance values were determined at
490 nm on a BioTek Instruments EL311 microplate reader.
2.5. Intracellular signaling
Seventy percent conﬂuent MCF-7 cells cultures were shifted to SFM for 24 h and
then treated with 10–500 nM peptide 13 or 6 nM full-sized leptin for 15 min–4 h,
or were left untreated in SFM. Next, the cells were lysed and proteins obtained
as described before [6]. 100 μg of total cell proteins were resolved on a 4–15%
polyacrylamide gel and the expression of phospho-ERK 1/2 and total ERK 1/2 was
detected by Western-blotting (WB) [6]. The Abs used were anti-ERK 1/2 and anti-
phospho Thr202/Tyr204 ERK 1/2 (Cell Signaling Technologies), both diluted at 1:1000
in TBST and 2% milk and HRP-conjugated secondary anti-rabbit Abs (1:1000 in TBST
and 2% milk, Santa Cruz Biotechnology).
2.6. In vitro BBB penetration assay
A conﬂuent monolayer of human astrocytes (designation C8D30, ATCC) or brain
capillary endothelial (designation bEND.1, ATCC) cells or a dual layer of both cell
types (ﬁrst astrocytes followed by endothelial cells) were grown at 37 °C on
polycarbonate ﬁlters (Costar, Transwell, 0.4 μm) pretreated with collagen. Under
these conditions, the endothelial cells retain the characteristics of BBB which in-
clude complex tight junctions, low rate of pinocytosis and enzyme levels [40]. A
solution of 0.01 mM of peptides 7, 12, 13, or 15 was added to the upper com-
partment of the Transwell plates and samples from the bottom compartments were
taken at 0, 5, 10, 30, 60 and 120 min intervals. The presence and amount of peptides
penetrated through the cell layers were analyzed by RP-HPLC and MALDI-MS. As
positive control, native leptin added to the upper chamber at 100 nMwas submitted
to the same process.
Upon completion of the BBB penetration assay, the biological activity of fractions
collected from the bottom Transwell chambers was tested using the XTT Cell
Proliferation Kit (Roche, Mannheim, Germany), following the manufacturer's instruc-
tions. Brieﬂy, MCF-7 cells were plated in 96-well culture plates at 4×103 cells/well in
normal culture medium. After 24 h, the mediumwas replaced with SFM for 24 h. Then,
the cells were exposed to 50 µL of BBB penetration experimental fractions for 72 h. Next,
the cells were incubated with XTT labelingmixture (ﬁnal XTTconcentration 0.3 mg/mL)
for 2 h at 37 °C. The formation of orange formazan dye product by metabolically active
cells was quantiﬁed on a BioTek Instruments EL311 microplate reader; the absorbance
was read at 450 nm using a reference wavelength at 650 nm. Cells stimulated with
100 ng/mL leptin for 72 h were used as controls.
2.7. In vivo biodistribution
Peptide 13 was co-synthesized with the near-infrared absorbing ﬂuorescent dye
DY675 and the labeled peptide was puriﬁed by RP-HPLC. 40 μg of the peptide wasModiﬁed residues Calculated molecular
weight (Da)
Mass found in
MALDI-MS (M/z)
1842.2 1843
1490.8 1490
Ala39, Ala40 1404.7 1404
2347.6 2348
Triglycine spacer 4344 4345
1652.8 1652
Ala120, Ala121 1606.8 1607
Tyr(I2)119, D-Gla122,
D-Ala126
1588.5 1589
Tyr(Me)119, D-Gla122,
D-Ala126
1297.6 1295
Tyr(I2)119, β-Ala126 1545.2 1545
Tyr(Me)119, β-Ala126 1248.6 1250
Tyr(I2)119, Ser(GlcAc4)120,
Dap(Ac)130
1946.6 1945
Tyr(I2)119, Ser(Glc)120,
Dap(Ac)130
1778.6 1780
Tyr(I2)119, Ser(GlcAc4)120,
Dap(Ac)130
2003.6 2005
etic byproduct 1056
la stands for D-γ-carboxyglutamic acid and Dap(Ac) stands for 2-acetamido-3-amino
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The animals were placed into the ﬂuorescence microscope chamber under continuous
isoﬂurane exposure. Fluorescence exposure pictures were taken with an IVIS micro-
scope set to 695 nm emission wavelength at every minute in the ﬁrst ten min after
peptide addition and every 5 min afterwards until 65 min.
3. Results
3.1. Peptide design and synthesis
Based on mutations in the full leptin protein, literature data
identiﬁed i–ii) helices A and C, iii) the hinge between helices A and B
and iv) the N-terminal ﬂanking region of helix D as parts of the three
discontinuous ObR ligand domains and potential antagonist sites in
leptin. First we synthesized all three potential ObR binding sites
individually and a composite of the two arms of site II separated with
a triglycine spacer. Table 1 lists the synthetic peptides and Fig. 1
shows their approximate location within leptin protein and their
relationship with the proposed ObR-binding leptin sites.
All leptin fragments were also made with a 5(6)-carboxy-
ﬂuorescein label at the N-terminus to examinemolecular interactions.
The ﬂuorescein-labeled peptides could be used for WB but not ﬂuo-
rescence polarization due to the insolubility of the available ObRFig. 2. Effects of construct 5 and peptide 7 on MCF-7 cell growth. The relative changes in cell
were determined as described in Materials andmethods. Panel A: treatment in the presence o
values.preparation (see below). When designing the native leptin fragments,
the following considerations were taken into account:
i) The amino-terminal sequence around leptin site I is ambiguous
in the literature. Here Val was selected to reduce ubiquitin-
mediated peptide degradation observed in full proteins [41];
ii) The sequences were extended to both termini relative to the
published binding sites to ensure proper folding around the
binding surfaces;
iii) If possible, helices were extended N-terminally until the pre-
ceding turns in order to retain helix initiation even in the pres-
ence of N-terminally attached ﬂuorescein label;
iv) The two site II fragments in the combined site II construct were
separated by three turn-forming glycine residues;
v) The N-terminus of site III was shortened to avoid predicted
synthetic difﬁculties;
vi) No sequence started with Gln that forms pyroglutamate during
puriﬁcation when placed at the N-terminus or ended with Thr
or Trp that make the ensuing solid-phase synthesis difﬁcult.
All syntheses were completed successfully, even for the quite large
combined site II construct (peptide 5) and ﬂuorescein-labeled analogs.
The peptides were puriﬁed by RP-HPLC and their integrity analyzed bynumber upon treatment with construct 5 and peptide 7 at 10 nM–1 μM concentrations
f exogenously added 6 nM leptin (L); panel B: without leptin addition. Bars represent SE
Table 2
Effects of different peptides on proliferation of DU-145 andMCF-10 cells in the presence
or absence of leptin
Peptide code Effects in DU-145 cells Effects in MCF-10 cells
No leptin 6 nM leptin No leptin
3 None Antagonist Toxic
5 Agonist Antagonist None
7 Agonist Antagonist None
12 ND ND None
13 ND ND None
The effects of various peptides at 1 μM concentration were studied in DU-145 ObR-
positive prostate cancer cells and in MCF-10 ObR-negative normal mammary epithelial
cells, as described in Materials and methods. Weak, moderate, strong agonist and
toxicity deﬁnitions of this table and Table 3 were made to be consistent with the text in
Results.
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the synthetic peptides.
3.2. Biological activity of the antagonist candidates
Biological activity the selected peptideswas tested onMCF-7 breast
cancer cells and DU-145 prostate cancer cells, both documented to
express ObR and respond to leptin stimulation with mitogenesis and
induction of intracellular signaling pathways [6,42]. Normalmammary
epithelial MCF-10 cells lacking ObR were used as negative control [7].
First we studied the biological properties of peptides 3 and 7 (Ala-
substituted site I and site III analogs)which, according to data on leptin
protein mutants [34,35] might display antagonistic activities. MCF-7
cells were stimulated with 6 nM full-sized leptin and the smaller
analogs were added at 10, 100 nM or 1 μM concentration. This test
group also contained peptide 5, the combined site II complex which,
due to the artiﬁcial spacer between the twoarms, can be also construed
as a potential antagonist derivative. Leptin at 6 nM concentration
stimulatedMCF-7 cell growth byapproximately 40% (Fig. 2, panel A), in
line with previous observations [6]. The combined site II construct 5
and the site III Ala derivative 7 antagonized leptin-induced cell pro-
liferation at 100nMconcentrations andproducedminor toxic effects at
1 μMdoses (Fig. 2, panel A). The activity of the site I derivative peptide 3Fig. 3. Effects of peptides 1, 2, 4, and 6 on MCF-7 cell growth. The relative changes in cell nu
determined as described in Materials and methods. Stimulation of cell growth by 6 nM nataltered from assay to assay, without producing statistically signiﬁcant
changes in cell growth until 100 nM concentration. However at 1 μM
peptide concentration, a reproducible 6% decrease in cell numbers
could be observed compared with the leptin only samples. In sum-
mary, in the presence of exogenously added full-sized leptin these
assays veriﬁed the strong antagonist activity of the site III alanine
mutant and the combined site II construct, but not that of the site I
alanine analog.
However, when the combined site II construct 5 and the site III Ala
mutant 7 were added to MCF-7 cells in the absence of leptin, both
peptides consistently exhibited strong agonistic activities especially at
100 nM and 1 μM concentrations (Fig. 2, panel B). The site I alanine
analog peptide 3 or an unrelated peptide (the antibacterial peptide
pyrrhocoricin) did not signiﬁcantly inﬂuence the growth of MCF-7 cell
proliferation at any dose (Fig. 2, panel B). Pyrrhocoricin, with a se-
quence of VDKGSYLPRPTPPRPIYNRNwas selected as a negative control
because it roughly equals in size the leptin fragments but with its Pro-
Arg-Pro repeats the sequence differs signiﬁcantly from the almost
neutral leptin analogs. The results obtained with DU-145 prostate
cancer cells largelymirrored those obtainedwithMCF-7 cells (Table 2).
While without leptin the site I alanine mutant peptide 3 was es-
sentially inactive (even less active than in MCF-7 cells), the combined
site II construct 5 and the site III alanine mutant 7 were medium-to-
strong agonists (Table 2). In the presence of leptin, all three peptides
showed moderate antagonist activities. None of the peptides had
major effects on the proliferation of the control MCF-10 cell line,
although peptide 3 showed minor toxic properties (Table 2). These
data indicate that the above leptin fragments are not true ObR an-
tagonists; rather they are partial agonists/antagonists depending upon
the presence or absence of other ObR ligands.
3.3. Activity of all native leptin fragments
The unmodiﬁed single arm leptin fragments showed variable
mitogenic potential in MCF-7 cells. Without leptin addition, peptides
2 and 6 (site I and the site III fragments) did not noticeably inﬂuence
the cell growth in the 10 nM–1 μM concentration range (Fig. 3).
Similarly, peptide 6 had no effect on the proliferation of either DU-145mber upon treatment with peptides 1, 2, 4, and 6 at 10 nM–1 μM concentrations were
ive leptin is shown for comparison. Bars represent SE values.
Fig. 4. Interaction of leptin peptides with ObR. Panel A: Binding of leptin fragments and
derivatives (numbers according to the Code in Table 1) to the extracellular domain of ObR
was assessed by dot-blot as described in Materials and methods. The experiments were
repeated 3 times. Panel B: Effects of peptides 12 and 13 at 100 nMand 1 μMconcentrations
onMCF-7cell growth in thepresenceorabsenceof6nMleptin (L). Bars represent SEvalues.
Table 3
Effects of different peptides on MCF-7 cell proliferation in the presence or absence of
leptin
Peptide code Biological effects
No leptin 6 nM leptin
8 Agonist Weak antagonist
9 Agonist Antagonist
10 Agonist Weak antagonist
11 Weak agonist None
The effects of 1 μM peptides were studied as described in Materials and methods. Weak
antagonists/agonists are considered if the cell numbers change less than 25% compared
to SFM or leptin.
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presence of 6 nM leptin, peptide 6 showed minor antagonistic activity
to ObR. The observed 21% reduction in leptin-induced cell growth at
1 μM is signiﬁcantly lower than that exhibited by peptide 7 (compare
with Fig. 2, panel B) indicating that the antagonist activities of the site
III alanine mutant peptide 7 in the presence of leptinwere indeed due
to the alanine substitutions. From the site II peptides, the C-terminal
70–89 fragment (peptide 4) appeared to be a stronger agonist without
exogenous leptin present than the N-terminal 3–18 fragment peptide
1 (Fig. 3). While both fragments promoted the proliferation of MCF-7
cells to some degree, the C-terminal site II arm at 1 μM resulted in
approximately 100% growth increase. In the presence of 6 nM
exogenous leptin, in agreement with previous observations on the
biological action of the leptin fragment 70–95 in rabbit endometrial
cells [14], both of our site II fragments exhibited antagonistic activities
against ObR.
While all peptides bound to the extracellular domain of ObR onWB,
assessing peptide–ObR binding by dot-blot appeared to be more dis-
criminative, and corresponded to the mitogenic stimulation results as
shown above (Fig. 4, panel A). In dot-blot assays the peptideswere dried
down on nitrocellulose sheets, and were incubated with a recombinant
extracellular ObR fragment. The strongest binding could be detected to
peptides 4 and 5, the site II C-terminal arm-containing samples. Peptide
7, the site III Ala,Ala derivative, was a medium-level, and peptide 1, the
N-terminal site II arm a weak binder. The three inactive peptides, the
two site I analogs (peptides 2 and 3) and the unmodiﬁed site III
fragment (peptide 6) did not bind ObR (Fig. 4, Panel A).
3.4. Designer site III derivatives
The results above suggested that site III carries strong partial an-
tagonist properties and represents a leptin region that can be further
modiﬁed for obtaining full ObR antagonists or perhaps agonists withtherapeutic potential. To this effect the peptide size was reduced to 12–
13 residues and hydrophobic or non-natural amino acidswere placed to
the termini to improve peptide stability in biological media (Table 1). In
two cases full C-terminal blockade was attempted with acetylated
diamino-propionic acid, a residue proven to increase peptide stability at
the C-terminuswithout interfering in vivo or in vitro biological activities
[43]. Selected aminoacid residueswere replacedwith unnatural analogs
also to increase stabilityaswell as introduce full antagonistic oragonistic
mutations. The modiﬁed residues included those that were shown to
regulate leptin activity [34,35] such as Tyr119 and Ser120 as well as
Glu122 and Ala125, two residues located at the one third and two third
positions of the new 12-mers. Tyr was replaced with the highly
homologousTyr(Me) or Tyr(I2), Gluwas replacedwithD-Gla (γ-carboxy-
glutamic acid) and Ala was replaced with β-Ala or D-Ala. The serinewas
replaced with Ser-β(GlcAc4) because a β-linked glucose moiety on
serine was shown to promote the penetration of an enkephalin analog
across the BBB [44]. The glycopeptide was tested both as sugar O-
acetylated and sugar side-chain deprotected (deacetylated) forms.
As with the site III derivative 7, peptides 8 and 9, featuring D-Gla
and D-Ala replacements were agonists to ObR in MCF-7 cells without
leptin addition and antagonists in the presence of leptin (Table 3).
Apparently the side-chain substituent on the tyrosine or the glycine
amino extension had no inﬂuence on the in vitro biological activity.
The β-alanine-containing 12-mer peptide 10 showed slightly stronger
activities on MCF-7 cells than its 13-mer variant 11 without dramatic
differences in the activity proﬁle (Table 3). Similar to the D-Gla, D-Ala
series, the shorter β-alanine-containing analog 10 was less agonistic
without the presence of leptin than the longer variant 11, and in the
presence of leptin the longer peptide exhibited weak antagonist ac-
tivitieswhile the shorter versionwas basically inactive. Taken together,
these site III analogs behaved very much like the combination of their
unmodiﬁed 6 and 7 parent leptin fragments. Once again in this group
no true agonist or antagonist could be identiﬁed.
A signiﬁcant advance came after screening the 12–14 glycopeptides.
Both the O-acetylated and the free peptides 12–13, just like their amino-
terminally extended analog 14, bound to the extracellular domain of
ObR by dot-blot (Fig. 4, panel A shows the strong binding of peptide 12).
An ELISA-type solid-phase binding assay demonstrated that 10 μg
peptide 12 dried on the plate yielded an absorbance reading 1.5 times of
the background; 20 μg had double of the background (data not shown).
The negative control antibacterial peptide pyrrhocoricin did not bind to
ObR by eithermethod. The poor solubility of the commercially available
ObR extracellular fragment— human Fc chimera in solvents suitable for
ﬂuorescence polarization prevented us from identifying accurate
binding constants in solution. However, we can estimate the approx-
imate EC50 from the dose required to trigger downstream signaling
events (see below). Based on the little effect of the N-terminally added
glycine at the peptide series 8–11 and to preserve researchmaterial, the
cell stimulation activity of peptide 14was not studied. Rather, we used it
to assess the serum stability of the glycopeptides (see Discussion).
Similar to most site III peptide fragments and analogs, glycopeptides 12
and 13 stimulated the proliferation of MCF-7 cells at 100 nM and 1 μM
Fig. 5. Effects of glycopeptide 13 (P13) on ERK 1/2 activation. Panel A: MCF-7 cells synchronized in SFM were treated for 15 min, 1 h or 4 h with either 6 nM leptin (L) or 100 nM
peptide 13 (P13). Panel B: SynchronizedMCF-7 cells were treated with 10–500 nM peptide 13 (P13). The expression of phospho-ERK1/2 and total ERK1/2 was determined byWBwith
speciﬁc Abs, as described in Materials and methods.
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data not shown). Nevertheless, as opposed to any other leptin fragment
and analog described above, the site III glycopeptides did not show any
leptin antagonistic activity. In fact, peptide 13 signiﬁcantly potentiated
leptin-induced cell growth at 100 nM and 1 μM concentrations, while
peptide 12 exhibited leptin-additive action at 100 nM (Fig. 4, panel B).
None of the peptides altered the growth of ObR-negative MCF-10 cells
(data not shown). Both glycopeptides 12 and 13 appeared to be full
agonists of ObR.
3.5. Effects of peptide 13 on intracellular signaling
The effects of peptide 13 (deacetylated site III agonist) on one of the
ObR downstream signals, the ERK1/2 pathway were assessed in MCF-7
cells (Fig. 5). In this cellularmodel,100 nMpeptide 13 stimulated ERK1/2
phosphorylation at 15min,1 h, and4hwith the efﬁcacy similar to that of
6 nM leptin (Fig. 5, panel A). After 15 min of peptide 13 treatment,
activation of phospho-ERK1/2 was noted at 100–500 nM peptide
concentrations. In several repeat experiments, the maximum of ERK1/2
stimulation was observed for 200 nM and half-maximum for 100 nM
doses (Fig. 5, panel B). On the basis of the band intensities in Fig. 5,
panel B, the EC50 value for peptide 13 against ObR-expressing cells was
estimated to be 100–150 nM, although it needs to be added that signal
transduction data bypass the ampliﬁcation that occurs during intracel-
lular signaling, and thus the half-inhibitory concentration (or the related
ObR-binding constant) was probably overestimated.
4. Discussion
The signaling pathways activated by ObR include the classic cytokine
JAK2/STAT3 pathway; the Ras/ERK1/2 signaling cascade; and the PI-3K/
Akt/GSK3 growth/anti-apoptotic pathway [28]. One can hypothesize
that inhibition of distinct interfaces will affect distinct downstreamObR
signaling pathways. A Ser120Ala/Thr121Ala leptin double mutant binds
the CRH2 domain of ObR but fails to induce proper STAT3 activation.
Thus, together with the measured in vitro and in vivo activities, it is
considered a true ObR antagonist [34]. However, our studies indicate
that at the peptide level the sequence variants that show antagonist
properties as proteins are actually partial agonists/antagonists, and this
is true for the individual site II C-terminal fragments as well. On one
hand, for some peptides, antagonism in the presence of leptin might be
explained by simple competition for receptor binding sites. On the other,
agonism in the absence of leptin might be due to the induction of
conformational changes in the receptor. We attempted to study this
hypothesis by circular dichroismmeasurements of the individual leptinfragments of this report and synthetic ObR fragments that corresponded
to proposed leptin-binding sites such as 325–334 [reported in [35]] or
499–513. Unfortunately the extreme insolubility of the receptor frag-
ments prevented the collection of any meaningful spectroscopic data.
Alternatively, peptide fragments inmultifunctional proteinsmay induce
different dominant downstream signaling events than those observable
with the full-sized proteins. A full analysis of all leptin-initiated path-
ways using the peptides of this report may bring a more deﬁnitive
explanation to our ﬁndings. Having said this, as a comparison of Figs. 3
and4A indicates, the bindingof the leptin fragments and their analogs to
ObRon the dot-blot assay, and stimulation ofObR-expressing cells could
be fully correlated. We observed the strongest binding to leptin
fragments carrying the C-terminal arm of site II. In native leptin,
mutations within site II can completely block binding to the receptor
suggesting that ObR afﬁnities of sites I and III to the receptor are too
weak to detect. Our results as presented here fully support this notion.
The reason for the antagonist/agonist activity of different peptides is
not clear. However, one can speculate that abnormal occupancy of ObR
in the presence of both leptin and leptin peptides may lead to enhanced
receptor internalization and degradation and consequently result in the
inhibition of cell growth or toxicity. Possibly, overactivation of ObRmay
also induce aberrant intracellular signaling that would be recognized as
a pro-apoptotic signal. These effects would not occur when only one
ligand is present. Second, the antagonistic activity of the single site
alanine mutants in full size leptin may originate from a cooperative
effect of the combined three sites, onemodiﬁed, two native. Potentially,
binding sites I and III have second arms, just as binding site II has. Since
the second arms of ObR binding sites I and III have not been identiﬁed
yet, a mixture of the 4 ObR binding sequences we investigated will still
lack crucial binding elements. Finally, alanine scans are usually used for
identiﬁcation of ligand-target binding characteristics and their antago-
nist properties are expectedly suboptimal compared to designer protein
and peptide drugs. For antagonist design in medicinal chemistry terms,
one has to turn to a big panel of unnatural amino acid mimics or
backbone modiﬁcation techniques [45].
The twomajor considerations for thedesignof the secondgeneration
site III derivatives were the stabilization against proteolytic degradation
and in the case of the planned agonist, improved crossing of the BBB. In
pooled mouse serum, the native site III fragment 6 was subject to both
amino- and carboxy-terminal cleavage according to mass spectroscopy.
The main degradation products after digestion with 25% serum for
45 min exhibited molecular masses of 1567, 1509, 1424 and 1366 cor-
responding to consecutive losses of Ser, Gly, Ser and Gly, the residues
found at both termini. Shortening of the sequence and incorporation of
non-natural amino acids into the amino termini of the designer analogs
Fig. 6.MALDI mass spectra of glycopeptides 13 (left) and 14 (acetylated and glycine extended, right) after 60-min incubation periods in pooled mouse serum at 37 °C. The main peaks
at 1780.7 and 2005.0 correspond to unmodiﬁedM+ of 13 and 14, respectively, with additional smaller M/z peaks present in the acetylated sample at 42 u apart indicating gradual loss
of the carbohydrate-protecting acetyl groups. No cleavage in the peptide chains or between the carbohydrate and the peptide backbones could be identiﬁed.
Table 4
Penetration of site III peptides across an artiﬁcial BBB cellular model
Peptide
code
Astrocytes Endothelial
cells
Astrocytes plus
endothelial cells
Biolocal activity of
peptides passed
through astrocytes
plus endothelial
cells after
5–10 min 30 min
12 10 min 10 min 10 min 64±2% 27±3%
13 10 min 5 min 10 min 27±4% 39±3%
15 60 min 30 min 30 min 3±0% 52±2%
7 30 min 30 min 30 min ND ND
The peptides at 10 μM concentration were tested in the BBB model as described in
Materials andmethods. Left three columns: The earliest time points of peptide detection
by mass spectroscopy in the lower compartment of Transwell ﬁlters are given. Far right
column: Biological activity (%±SD vs unstimulated control) of peptides collected from
the bottom Transwell compartments at 5–10 min or 30 min post-application. In control
experiments, 6 nM leptin passed through the astrocyte/endothelial cell layer for 10 min
increased the growth of MCF-7 by 30%, while externally added 6 nM leptin stimulated
the cells by 58% over the control. ND, not determined.
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remained intact under identical digestion conditions as measured by a
more accurate HPLC analysis of peak heights. Interestingly, the three
main degradation products corresponded to losses of Tyr(Me) and Ser,
the two amino terminal residues in spite of the methylated tyrosine
placed at the terminus. Ultimately the stabilization process led to the
complete resistance of the N- and C-terminally protected glycopeptides
to serum degradation. As Fig. 6 shows, no amino acid residues or the
carbohydrate moiety were cleaved from glycopeptides 13 or 14 after as
long as 60-min incubation in 25% mouse serum. The major metabolites
of the acetylated peptide 14 corresponded to the quasimolecular ion,
with a series of partially deacetylated products dispersed at 42 u apart.
In contrast to potential antagonists that have to recognize ObR on
tumor cell surface and have to act in the extracellular milieu for cancer
control, the newly discovered agonists have to cross the BBB to reach
the hypothalamus. Glycosylation of enkephalin analogs improves both
stability of peptide drugs and their penetration across the BBB [46], our
long-term goals for the leptin agonists. The tyrosine was iodinated
because in addition to glycosylation, it was speculated that iodination
may improve the activity of the enkephalin-based glycopeptides in the
brain in situ [46]. Our preliminary serum stability studies indicated
that the only early cleavage sites on the glycopeptides are the sugar-
protecting acetyl groups. Although the deacetylated glycopeptide 13
showed cell stimulatory properties very similar to the protected analog
12, the acetylated version appeared to bind to ObR on the solid-phase
at lower concentrations (below 100 nM), and thus additional
experiments have to be performed to document that acetyl removal
is indeed advantageous. While sugar incorporation generally reduces
the ability of the enkephalin-glycopeptides to bind to their receptors,
the orientation of the anomeric carbon has little effect. Thus it is
possible that it is the bulk of the carbohydrate that provides a reduced
level of ObR binding and thus modiﬁcation of the agonist/antagonistproﬁle of our glycopeptides compared to other site III analogs. In
addition, increased hydrophobicity improves penetration across the
BBB [44], and the acetyl groups may serve a beneﬁcial role in that
process. To study what, if anything, drives the leptin peptides through
the BBB, we studied the penetration of the protected 12 and free 13
glycopeptides across conﬂuent layers of astrocytes, brain endothelial
cells, or a double layer of these two, in comparison with an N-ter-
minally acetylated but non-glycosylated analog 15 that was a synthetic
byproduct during the preparation of peptides 12/13, and the non-
acetylated non-glycosylated site III analog 7. The applied cell model
was shown to mimic the transport properties of drugs across the BBB
accurately [40]. In this set of experiments, all four peptides penetrate
Fig. 7. Biodistribution of glycopeptide 13 labeled with the DY675 stain at its N-terminus.
The picture shows the labeled peptide distributed into the two kidneys and liver as well
as the head of a Balb/c mouse at 60 min after intraperitoneal injection.
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time point when the two non-glycosylated peptides could be detected
by mass spectrometry was as late as 30 min, the glycopeptides were
present in the bottom Transwell compartment as early as 5–10 min
after addition. This suggests that it was the presence the carbohydrate
side-chain on the serine residue that promoted penetration across the
dual layer of cells.
The sensitivity of mass spectroscopy was exploited to determine
whether the observed level of BBB penetration had any biological
signiﬁcance. Thus, we tested the samples collected from the bottom
Transwell compartments for their ability to stimulate cell growth
(measured as increase of metabolic activity of the culture) (Table 4).
From this measure it was clear that in each case when mass
spectroscopy detected leptin fragments (or native leptin protein
used as control) passing through the dual layer of cells, the amount
of peptide/protein was sufﬁcient to activate ObR-expressing cells.
Considering that the glycopeptides reproducibly stimulated the
growth of MCF-7 cells at 100 nM, the initial 10 μM peptide dose in
the upper chamber and the relative volumes of the two chambers, at
least 5% of the loaded peptides must have passed the BBB cell layer.
To further prove that glycopeptide 13 indeed might travel to the
brain, the biodistribution of aDY675 labeled analogwas investigated in
vivo. The DY675 stain absorbs and emits light in the near-infrared
region, and the generated long-wavelength ﬂuorescence canpenetrate
through the thin layers of mouse tissues without background
ﬂuorescence from biopolymers and can be recorded by microscopic
techniques [47]. Fig. 7 shows that 60 min after intraperitoneal
injection, the glycopeptide was distributed into the kidneys, the liver
and the head. Renal and hepatic clearance is the major elimination
mechanism of peptide drugs [48]. In addition to the clearance organs, a
major biodistribution site was the head, suggesting that glycopeptide
13 does cross the BBB in vivo.
Our data indicate that those leptin analogs that are full antagonists
of the native protein remain only partial agonists at the peptide level.
While full peptide antagonists are still to be discovered, we have
identiﬁed a family of full agonists to the leptin receptor. Intraper-itoneal administration of a leptin fragment located between our site II
fragment b and site III peptides (note the amino acid numbering
differences between the earlier article and our current contribution;
the former included the signal sequence) to ob/ob mice was found to
result in weight loss and decreased food uptake [49]. This was
considered a major advancement because intracranial administration
of recombinant leptin induces more extensive weight loss in ex-
perimental animals than intramuscular or even intraventricular drug
addition [50]. Later, the minimally active peptide was identiﬁed as the
Ser-Cys-Ser-Leu-Pro-Gln-Thr heptapepetide fragment [51]. Since the
active peptide neither binds ObR nor promotes its characteristic sig-
naling pathways [52], the authors posed a hypothesis that themode of
action of the heptapeptide leptin fragment is to bind the melano-
cortin-4 receptor instead [53]. This explanation meant to answer the
question how a peripherally added leptin fragment can have CNS
effects when the full protein is excluded from the CNS in obese mice
[54]. Here we show that with appropriate medicinal chemistry mod-
iﬁcations, we are able to produce a leptin fragment that passes the BBB
in vitro and mimics native leptin actions including binding to ObR and
induction of cell signaling.
In conclusion, leptin binding site III appears to be suitable for
medicinal chemistry manipulations to improve the pharmacological
properties of the peptide drug leads. The biological activities and
preliminary pharmacological parameters of the site III designer gly-
copeptides 12 and 13 warrant further studies evaluating their activity
in animal models of leptin deﬁciency or dysfunction.
Acknowledgements
The authors would like to thank Dr. Paraskevi Vogiatzi and Ms
Donatella Cirillo their advice and devoted technical assistance.
Professor Mohammad F. Kiani and Mr. Fred Donelson are thanked
for their assistancewith the IVISmicroscope. This workwas supported
by the by the Formula Fund of the PA Department of Health and by the
Sbarro Health Research Organization.
References
[1] M. Wauters, R.V. Considine, L.F. Van Gaal, Human leptin: from an adipocyte
hormone to an endocrine mediator, Eur. J. Endocrinol. 143 (2000) 293–311.
[2] Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional
cloning of the mouse obese gene and its human homologue, Nature 372 (1994)
425–432.
[3] K.M. Lo, J. Zhang, Y. Sun, B. Morelli, Y. Lan, S. Lauder, B. Brunkhorst, G. Webster,
S. Hallakou-Bozec, L. Doare, S.D. Gillies, Engineering a pharmacologically
superior form of leptin for the treatment of obesity, Prot. Eng. Des. Sel. 18
(2005) 1–10.
[4] C. Garofalo, E. Surmacz, Leptin and cancer, J. Cell. Physiol. 207 (2006) 12–22.
[5] M.N. Dieudonne, F. Machinal-Quelin, V. Serazin-Leroy, M.C. Leneveu, R. Pecquery,
Y. Giudicelli, Leptin mediates a proliferative response in human MCF-7 breast
cancer cells, Biochem. Biophys. Res. Commun. 293 (2002) 622–628.
[6] C. Garofalo, D. Sisci, E. Surmacz, Leptin interferes with the effects of the
antiestrogen ICI 182,780 in MCF-7 breast cancer cells, Clin. Cancer Res. 10 (2004)
6466–6475.
[7] X. Hu, S.C. Juneja, M.J. Maihle, M.P. Cleary, Leptin-a growth factor in normal and
malignant breast cells and for normal mammary gland development, J. Natl.
Cancer Inst. 94 (2002) 1704–1711.
[8] M. Ishikawa, J. Kitayama, H. Nagawa, Enhanced expression of leptin and leptin
receptor (OB-R) in human breast cancer, Clin. Cancer Res. 10 (2004) 4325–4331.
[9] M. Koda, M. Sulkowska, L. Kanczuga-Koda, S. Cascio, G. Colucci, A. Russo, E.
Surmacz, S. Sulkowski, Expression of the obesity hormone leptin and its receptor
correlates with hypoxia-inducible factor-1α in human colorectal cancer, Ann.
Oncol. 18 (2007) vi116–vi119.
[10] E. Surmacz, Obesity hormone leptin—a new target in breast cancer? Breast Cancer
Res. 9 (2007) 301.
[11] M. Koda, M. Sulkowska, L. Kanczuga-Koda, E. Surmacz, S. Sulkowski, Over-
expression of obesity hormone leptin in human colorectal cancer, J. Clin. Pathol. 60
(2007) 902–906.
[12] C. Garofalo, M. Koda, S. Cascio, M. Sulkowska, L. Kanczuga-Koda, J. Golaszewska, A.
Russo, S. Sulkowski, E. Surmacz, Increased expression of leptin and the leptin
receptor in primary and metastatic breast cancer: possible role of obesity-related
stimuli, Clin. Cancer Res. 12 (2006) 1447–1453.
[13] L. Tessitore, B. Vizio, D. Pesola, F. Cecchini, A. Mussa, J.M. Argiles, C. Bendetto,
Adipocyte expression and circulating levels of leptin increase in both gynaecolo-
gical and breast cancer patients, Int. J. Oncol. 24 (2004) 1529–1535.
1754 L. Otvos Jr. et al. / Biochimica et Biophysica Acta 1783 (2008) 1745–1754[14] R.R. Gonzalez, P.C. Leavis, A peptide derived from the human leptin molecule is
a potent inhibitor of the leptin receptor function in rabbit endometrial cells,
Endocrine 21 (2003) 185–195.
[15] R.R. Gonzalez, S. Cherﬁls, M. Escobar, J.H. Yoo, C. Carino, A.K. Styer, B.T. Sullivan, H.
Sakamoto, A. Olawaiye, T. Serikawa, M.P. Lynch, B.R. Rueda, Leptin signaling
promotes the growth of mammary tumors and increases the expression of
vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2),
J. Biol. Chem. 281 (2006) 26320–26328.
[16] L.A. Tartaglia, The leptin receptor, J. Biol. Chem. 272 (1997) 6093–6096.
[17] D.W. White, K.K. Kuropatwinski, R. Devos, H. Baumann, L.A. Tartaglia, Leptin
receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence
for receptor homo-oligomerization, J. Biol. Chem. 272 (1997) 4065–4071.
[18] V.A. Barr, K. Lane, S.I. Taylor, Subcellular localization and internalization of the four
human leptin receptor isoforms, J. Biol. Chem. 274 (1999) 21416–21424.
[19] C. Bjorbaek, S. Uotani, B. da Silva, J.S. Flier, Divergent signaling capacities of
the long and short isoforms of the leptin receptor, J. Biol. Chem. 272 (1997)
32686–32695.
[20] N.M. Morton, V. Emilsson, P. de Groot, A.L. Pallett, M.A. Cawthorne, Leptin
signalling in pancreatic islets and clonal insulin-secreting cells, J. Mol. Endocrinol.
22 (1999) 173–184.
[21] M. Buyse, M.L. Ovesjo, H. Goiot, S. Guilmeau, G. Peranzi, L. Moizo, F. Walker, M.J.
Levin, B. Meister, A. Bado, Expression and regulation of leptin receptor proteins
in afferent and efferent neurons of the vagus nerve, Eur. J. Neurosci. 14 (2001)
64–72.
[22] H. Goiot, S. Attoub, S. Kermorgant, J.P. Laigneau, B. Lardeux, T. Lehy, M.J. Lewin, A.
Bado, Antral mucosa expresses functional leptin receptors coupled to STAT-3
signaling, which is involved in the control of gastric secretions in the rat,
Gastroenterology 121 (2001) 1417–1427.
[23] F. Akerman, Z.M. Lei, C.V. Rao, Human umbilical cord and fetal membranes co-
express leptin and its receptor genes, Gynecol. Endocrinol. 16 (2002) 299–306.
[24] Y.J. Lee, J.H. Park, S.K. Ju, K.H. You, J.S. Ko,H.M. Kim, Leptin receptor isoformexpression
in rat osteoblasts and their functional analysis, FEBS Lett. 528 (2002) 43–47.
[25] G.S. Kim, JS. Hong, S.W. Kim, M. Koh, C.S. An, J.Y. Choi, S.L. Cheng, Leptin induces
apoptosis via ERK/cPLA2/cytochrome c pathway in human bone marrow stromal
cells, J. Biol. Chem. 278 (2003) 21920–21929.
[26] C. Bjorbaek, R.M. Buchholz, S.M. Davis, S.H. Bates, D.D. Pierroz, H. Gu, B.G. Neel,M.G.
Myers Jr., J.S. Flier, Divergent roles of SHP-2 in ERK activation by leptin receptors,
J. Biol. Chem. 276 (2001) 4747–4755.
[27] G. Sweeney, Leptin signalling, Cell. Signal. 14 (2002) 655–663.
[28] L. Zabeau, D. Lavens, F. Peelman, S. Eyckerman, J. Vandekerckhove, J. Tavernier, The
ins and outs of leptin receptor activation, FEBS. Lett. 546 (2003) 45–50.
[29] K.A. Frankenberry, P. Somasundar, D.W. McFadden, L.C. Vona-Davis, Leptin induces
cell migration and the expression of growth factors in human prostate cancer cells,
Am. J. Surg. 188 (2004) 560–565.
[30] R.S. Ahima, Central actions of adipocyte hormones, Trends Endocrinol. Metab. 16
(2005) 307–313.
[31] W. Pan, A.J. Kastin, Polypeptide delivery across the blood–brain barrier, Curr. Drug
Targets CNS Neurol. Disord. 3 (2004) 131–136.
[32] F. Zhang, Y. Chen, M. Heiman, R.D. Dimarchi, Leptin: structure, function and
biology, Vitam. Horm. 71 (2005) 345–372.
[33] F. Zhang, M.B. Basinski, J.M. Beals, S.L. Briggs, L.M. Churgay, D.K. Clawson, R.D.
DiMarchi, T.C. Furman, J.E. Hale, H.M. Hsiung, B.E. Schoner, D.P. Smith, X.Y. Zhang, J.P.
Wery, R.W. Schevitz, Crystal structure of the obese protein leptin-E100, Nature 387
(1997) 206–209.
[34] F. Peelman, K. Van Beneden, L. Zabeau, H. Iserentant, P. Ulrichts, D. Defeau, A.
Verhee, D. Catteeuw, D. Elewaut, J. Tavernier, Mapping of the leptin binding sites
and design of a leptin antagonist, J. Biol. Chem. 279 (2004) 41038–41046.
[35] L. Niv-Spector, D. Gonen-Berger, L. Gourdou, E. Biener, E.E. Gussakovsky, Y.
Benomar, K.V. Ramunajan, M. Taouis, B. Herman, I. Callebaut, J. Djiane, A.
Gertler, Identiﬁcation of the hydrophobic strand in the A–B loop of leptin as
major binding site III: implications for large-scale preparation of potentrecombinant human and ovine leptin antagonists, Biochem. J. 391 (2005)
221–230.
[36] H. Iserentant, F. Peelman, D. Defeau, J. Vandekerckhove, L. Zabeau, J. Tavernier,
Mapping the interface between leptin and the leptin receptor CHR2 domain, J. Cell
Sci. 118 (2005) 2519–2527.
[37] G.B. Fields, R.L. Noble, Solid-phase peptide synthesis using 9-ﬂuorenylmethox-
ycarbonyl amino acids, Int. J. Pept. Protein Res. 35 (1990) 161–214.
[38] M.F. Powell, T. Stewart, L. Otvos Jr., L. Urge, F. Gaeta, A. Sette, T. Arrhenius, D.
Thomson, K. Soda, S.M. Colon, Peptide stability in drug development. II. Effect of
single amino acid substitution and glycosylation peptide reactivity in human
serum, Pharmacol. Res. 10 (1993) 1268–1273.
[39] L. Otvos Jr., G.I. Szendrei, Enzyme-linked immunosorbent assay of peptides, in: G.B.
Irvine, C.H. Williams (Eds.), Neuropeptide Protocols, Humana Press, Totowa, NJ,
1996, pp. 269–275.
[40] S. Lundquist, M. Renftel, J. Brillault, L. Fenart, R. Cecchelli, M.-P. Dehouck,
Prediction of drug transport through the blood–brain barrier in vivo: a comparison
between two in vitro cell models, Pharm. Res. 19 (2002) 976–981.
[41] A. Varshavsky, The N-end rule: functions, mysteries, uses, Proc. Natl. Acad. Sci. U. S. A.
93 (1996) 12142–12149.
[42] C. Garofalo, M. Koda, S. Cascio, M. Sulkowska, L. Kanczuga-Koda, J. Golaszewska, A.
Russo, S. Sulkowski, E. Surmacz, Increased expression of leptin and the leptin
receptor as a marker of breast cancer progression: possible role of obesity-related
stimuli, Clin. Cancer Res. 12 (2006) 1447–1453.
[43] L. Otvos Jr., K. Bokonyi, I. Varga, B.I. Otvos, R. Hoffmann, H.C.J. Ertl, J.D. Wade, A.M.
McManus, D.J. Craik, P. Bulet, Insect peptides with improved protease-resistance
protect mice against bacterial infection, Protein Sci. 9 (2000) 742–749.
[44] R. Polt, F. Porreca, L.Z. Szabo, E.J. Bilsky, P. Davis, T.J. Abbruscato, T.P. Davis, R.
Horvath, H.I. Yamamura, V.J. Hruby, Glycopeptide enkephalin analogues produce
analgesia in mice; evidence for penetration of the blood–brain barrier, Proc. Natl.
Acad. Sci. U. S. A. 91 (1994) 7114–7118.
[45] M. Cai, A.V. Mayorov, J. Ying, M. Stankova, D. Trivedi, C. Cabello, V.J. Hruby, Design
of novel melanotropin agonists and antagonists with high potency and selectivity
for human melanocortin receptors, Peptides 26 (2005) 1481–1485.
[46] R.D. Egleton, S.A. Mitchell, J.D. Huber, J. Janders, D. Stropova, R. Polt, H.I. Yamamura,
V.J. Hruby, T.P. Davis, Improved bioavailability to the brain of glycosylated Met-
enkephalin analogs, Brain Res. 881 (2000) 37–46.
[47] V. Ntziachristos, C. Bremer, R. Weissleder, Fluorescence imaging with near-infrared
light: new technological advances that enable in vivo molecular imaging, Eur.
Radiol. 13 (2003) 195–208.
[48] W. Klootwijk, E. Sleddens-Linkels, R. de Boer, C.A. Jansen, R. Autar, W.W. de Herder,
E.R. Boeve, T.J. Visser, V.J. de Grief, Renal clearance of the thyrotropin-releasing
hormone-like peptide pyroglutamyl–glutamyl–prolineamide in humans, J. Clin.
Endocrinol. Metab. 82 (1997) 3068–3073.
[49] P. Grasso, M.C. Leinung, S.P. Ingher, D.L. Lee, In vivo effects of leptin-related synthetic
peptides on bodyweight and food intake in female ob/obmice: localization of leptin
activity to domains between amino acid residues (106–140), Endocrinology 138
(1997) 1413–1418.
[50] C. Lundberg, S.J. Jungles, R.C. Mulligan, Direct delivery of leptin to the hypothalamus
using recombinant adeno-associated virus vectors results in increased therapeutic
efﬁcacy, Nat. Biotech. 19 (2001) 169–172.
[51] M. Rozhavskaya-Arena, D.W. Lee, M.C. Leinung, P. Grasso, Design of a synthetic
leptin agonist: effects on energy balance, glucose homeostasis, and thermoregula-
tion, Endocrinology 141 (2000) 2501–2507.
[52] P. Grasso, D.W. White, L.A. Tartaglia, M.C. Leinung, D.W. Lee, Inhibitory effects of
leptin-related synthetic peptide 116–130 on food intake and body weight gain in
female C57BL/6J ob/obmice may not be mediated by peptide activation of the long
isoform of the leptin receptor, Diabetes 48 (1999) 2204–2209.
[53] P. Grasso, D.W. Lee, M.C. Leinung, Leptin-related peptides. US Patent 7,208,572
(2007)
[54] W.A. Banks, C.R. DiPalma, C.L. Farrel, Impaired transport of leptin across the blood–
brain barrier in obesity, Peptides 20 (1999) 1341–1345.
